Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GiGA1 (G protein-independent GIRK Activator 1) is a selective, small-molecule agonist of G protein-gated inwardly rectifying potassium (GIRK) channels, specifically targeting GIRK1/GIRK2 heterotetramers. Discovered through a structure-based virtual screening of the alcohol-binding pocket in GIRK channels, GiGA1 acts in a G-protein-independent manner to activate GIRK1-containing channels with rapid activation and deactivation kinetics. By enhancing potassium conductance, GiGA1 hyperpolarizes neurons and reduces excitability in the brain. It has demonstrated preclinical efficacy as an anticonvulsant in animal models of acute chemoconvulsant-induced seizures and tumor-associated epilepsy (TAE), and is also being investigated for its potential to reduce alcohol-mediated behaviors in models of alcohol use disorder (AUD).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on GiGA1.